Quantcast

Monomer-Polymer and Dajac Labs is Pleased to Announce the Acquisition of IsoSciences

December 2, 2011

Monomer-Polymer and Dajac Labs announced today that it has acquired IsoSciences, LLC.

Trevose, PA (PRWEB) December 02, 2011

Monomer-Polymer and Dajac Labs today announced it has completed the acquisition of IsoSciences, LLC, a privately-held manufacturer of stable isotope-labeled hormones, vitamins and specialty organic chemicals, located in King of Prussia, Pennsylvania. IsoSciences, will become a subsidiary of the parent MPD Holdings and will complement MPDâs existing portfolio of specialty and performance chemicals.

Research and development of novel materials for demanding industries is the core of MPDâs success and growth over the last 35 years. The recent integration of Monomer-Polymer and Silar has garnered many recent successes for MPD, creating solutions for technically challenging projects in the biomedical device, dental, wound care, and electronics industries. The success of this interdisciplinary research is based not only the ability to create new molecules, but also on gaining a fundamental understanding of the underlying mechanisms and modes of action. With the addition of IsoSciences, MPD will have the ability to create molecules with easily detected markers, allowing MPD to create additional solutions using stable isotope labeled materials.

Monomer-Polymer and Dajac Labs has undertaken specialty monomer and polymer research for over 50 years, creating an extensive datacenter of highly technical monomers and related polymers and copolymers. MPD specialties include acrylates, methacrylates, fluorinated molecules, silanes and vinyl monomers, in addition to the corresponding polymers and copolymers. MPD’s specialty monomers and polymers are broadly used, serving many markets including coatings, adhesives, medical devices, dental resins, wound care, academic and industrial R&D.

IsoSciences is a world leader in providing custom synthesized isotope labeled compounds including intermediates, final drug substances, and isotopically labeled biological standards. Molecule development is undertaken with a focus on servicing pharmaceutical companies and other research organizations that require isotopically labeled compounds and other non-labeled organic intermediates as well as metabolites. The Companyâs chemists have more than 100 yearsâ combined experience preparing isotopically labeled compounds and non-labeled organic intermediates and metabolites.

âœIncorporation of stable isotope labels into our current specialty chemicals offers many exciting opportunities for the development of materials utilizing knowledge of underlying mechanisms. IsoScienceâs experienced management and diverse technical teams in collaboration with the organosilane and specialty monomer business units will allow MPD to further diversify its technical offering by creating unique stable isotope labeled materials and production of pharmaceutical precursors and intermediates,â said Stephen Bell, CEO of MPD. âœWe are excited to have IsoSciences join our organization and look forward to developing these opportunities with them.â

Scott Landvatter, CEO of Isosciences said, âœJoining forces with a high quality specialty chemical producer like MPD offers IsoSciences the greatest potential for growing our business, expanding our capabilities and maximizing value for our customers.â

For more information on this transaction, please contact Stephen Bell, Ph.D.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/12/prweb9009696.htm


Source: prweb



comments powered by Disqus